Thirty percent: the upper end of the scale that has shifted over time

What exactly does the thirty percent declaration on the raw material label measure?

The declaration describes the share of tetrahydrocannabinol in the mass of dried flower, converted from the acidic form to the neutral form, and not the strength of the perceived effect. The manufacturer provides a nominal value, to which a tolerance of ten percent is added, so thirty percent means material that falls between twenty-seven and thirty-three percent.

In dried flower, tetrahydrocannabinol mainly exists in the acidic form, which does not bind to the receptors of the endocannabinoid system. Only heating detaches a carbon dioxide molecule from it and converts it into an active form. Therefore, the number on the package is a converted value: it indicates how much active substance can be obtained from the raw material after heating, not how much is present in the raw material at the time of dispensing from the pharmacy. This principle applies to every declaration, but at the upper end of the scale, the conversion concerns a larger mass.

A tolerance of ten percent of the nominal value is not a minor margin here. At thirty percent, the range reaches six percentage points, which is more than the gap between two neighboring positions from the middle of the range. The ranges of neighboring declarations overlap as a result. co rozwijamy na stronie o osiemnastu procentach. Osobno stoi pytanie, na ile deklaracja z certyfikatu serii odpowiada temu, co pokazuje pomiar, i temu we dedicate a page to twenty percent. For the current assortment, we refer you to list of available strains, because this page describes the number, not the offer.

Why did thirty percent lie outside the scale two decades ago?

Because the scale has shifted over half a century. A meta-analysis published in the journal Addiction showed that the concentration of tetrahydrocannabinol in hemp has increased from year to year, in dried flower by about 0.29 percentage points annually, in samples collected from 1970 to 2017. The material we now call strong was not available in circulation back then.

The work of Freeman and co-authors is not a single measurement, but a systematic review with a meta-analysis of concentration changes over time: it included twelve studies from seven countries and over sixty-six thousand samples of dried flower. For resin, the rate was higher, at about 0.57 percentage points per year. The concentration of cannabidiol in the same material did not change in a way that could be demonstrated, so it was not the content of everything that increased, but just one substance (PMID:33160291).

For the page about thirty percent, this result has direct implications. The upper end of the offer is not static: the number that today represents the strongest available material had no equivalent in raw material two decades ago. The increase measured in tenths of a point looks modest on a yearly scale and gives several points on a generational scale, and it is precisely on this scale that literature on hemp is read today.

What does the shifting scale do to the results of older studies?

It underestimates exposure. Work conducted on material from years past describes something weaker than what is available in pharmacies today, so transferring its results directly to today's products leads the reader to think of a smaller amount of active substance than is actually involved with the same mass of dried flower.

This consequence is inconvenient for the entire literature on hemp, as it concerns not one study, but entire generations. The review by Petrilli and co-authors from The Lancet Psychiatry included only observational studies, and its authors noted the lack of a uniform measure of exposure (PMID:35901795). Without such a measure, it is impossible to say how much active substance participants from a decade ago were taking compared to participants studied today, and without that, comparing risk between generations remains an approximation.

At thirty percent, the problem is the sharpest, as it represents the upper end of today's pharmacy offer. The higher up the scale, the fewer older studies describing comparable material, and the fewer such studies, the more inference by analogy is required. This is evident even in the registry data collected for this overview: of eighty-five cultivars, sixty-nine have a declared content, the highest nominal declaration read from them is twenty-nine percent, and sixteen positions do not have a tolerance stated at all. Declarations of thirty percent are not yet present in this collection, although such positions have already appeared in pharmacies.

Does the word 'strong' have a fixed point of reference?

No, it does not. What today stands at the upper end of the offer lay outside the scale of available material two decades ago, and what was then called strong is now in the middle of the range. The word thus describes a position in the market of a given year, not a property of the plant.

This is evident from how the literature has to deal with the division into categories. The authors of the review from The American Journal of Psychiatry built a division corresponding to the real market, from the lowest ranges to concentrates, and the very fact that such a division had to be constructed for the needs of one paper speaks to the lack of a common reference framework (PMID:40134269). We dedicate a separate page to potency categories drawn from the literature. procentach.

A moving point of reference has very practical implications. The statement 'I have already had strong dried flower' says nothing until it is known what year that memory comes from and what declaration stood behind it. For the same reason, comparing experiences between individuals treated in different years leads to dead ends, and the only place where the number returns to its place is a conversation with the attending physician about a specific registry position. The same caution applies to descriptions found online: a mention of strong dried flower without a stated declaration and without a date carries no information that could be verified.

How is the strength of the raw material matched to the patient?

The attending physician decides, not the number on the package. The declared percentage describes the raw material, not the dose: the same content provides a different amount of active substance with a different mass of dried flower and a different route of administration. Positions from the upper end of the scale are practically given to individuals with established tolerance.

Tolerance changes what the same content does to a specific person. In a patient who has been using hemp for a long time, the reaction to the same raw material may be weaker than in someone who is just starting, so two doses with identical declarations are not equivalent. The difference then lies not in the dried flower, but in the recipient, and the website has no way to assess it.

The method of reaching the dose, or titration, is described on the page about twenty-two percent. and details should be sought there. Here remains the observation arising from the topic of this page: since the scale has shifted over time, one's own experience from years past is also not a good starting point. The choice of registry position belongs to the physician, who knows the diagnosis and other medications being taken, and dispensing raw material in the Rpw category still requires a prescription.

Does the declared percentage change the onset of action and its duration?

It does not. The onset and duration of the episode are determined by the route of administration, while the declared content indicates how much active substance is carried by a given portion, not when it will start to take effect. With a higher declaration, the same mass of dried flower simply carries more substance in the same amount of time.

The route of administration determines the course more than the variety itself. After vaporization, the substance passes from the lungs to the blood almost immediately, so the first sensations appear after a few minutes, the intensity increases for another ten to thirty minutes, and the whole effect lasts for two to four hours. After ingestion, the raw material first passes through the intestine and liver, so the first sensations are awaited from half an hour to two hours, and the episode can last six, sometimes eight hours. Hence the most common mistake with oral administration: anyone who thinks nothing is happening after thirty minutes and takes another dose will receive both doses at once. The above ranges describe the route of administration, not this variety; pharmacokinetic studies for a single cultivar have not been published.

For material at the upper end of the scale, there is one practical difference. A mistake with oral administration costs more because it concerns a portion with a higher content, not because the episode proceeds differently over time. No one has measured the course of action separately for thirty percent raw material and separately for weaker ones, so the intervals provided above remain a description of the route of administration, not a description of this declaration.

What is known, and what is not known about the relationship between the potency of the raw material and the effect?

It is known that higher potency is associated with more frequent problematic use of hemp and a higher risk of psychosis. It is not known whether it translates into a better therapeutic effect: the evidence pertains almost exclusively to adverse effects and non-medical use, and the certainty of the evidence has been rated as very low by the authors of the latest reviews.

The four studies on which this page is based discuss different things and differ in their research model, so each one has its own model.

The discrepancy between these studies is information, not a flaw. The review from Annals of Internal Medicine found nearly half of the beneficial results for anxiety and depression among studies on therapeutic use, but some of the same studies also noted negative associations, and the risk of systematic error was rated as moderate or high in over ninety-five percent of the material included in the review (PMID:40854216). The review from The American Journal of Psychiatry rated the overall certainty of evidence as very low, and the review from The Lancet Psychiatry relied solely on observational studies, where exposure is inferred from what participants reported.

For a single declaration, including for thirty percent, there is no separate result. Categories used in the literature encompass broad ranges, not specific registration positions, so these reviews cannot reveal how thirty percent raw material differs from twenty-seven percent.

What adverse effects are associated with higher potency raw material?

The same ones that are described for dried flower in general, except that with a higher declaration, it is easier to obtain them with the same mass of raw material. There is no separate compilation of frequency for thirty percent material because reports are collected for the medicinal product with a batch number, not for the declared potency.

Reports of adverse effects are collected for medicinal products with a batch number, not for the strain name, so the following pertains to hemp dried flower as a group of raw materials. The most frequently reported symptoms are dry mouth, red eyes, and increased heart rate. Dizziness upon rapid standing, daytime drowsiness, and temporary worsening of short-term memory are less frequently described, as well as anxiety that increases with dosage. A separate issue is medications taken concurrently, especially sedatives and those affecting coagulation: their assessment requires knowledge of the entire list of preparations, not just the description of the plant. We do not provide the frequency of these symptoms numerically, as public compilations for hemp dried flower in Poland do not separate them by individual products.

As for the dependency on potency itself, the reviews collected above discuss more frequent problematic use and a higher risk of psychosis with stronger products, but they do so based on observational studies and with the certainty of evidence assessed as very low. We dedicate a separate page to adverse effects about twenty-seven. procentach, here it remains just a note that a higher declaration does not change the list of symptoms, it changes the mass of raw material at which they appear.

Frequently Asked Questions about the declared potency of dried flower

Does a higher declared percentage mean stronger therapeutic effects?

It has not been shown that a higher declared percentage on the label indicates stronger or better therapeutic effects. The evidence regarding the potency of the raw material pertains almost exclusively to adverse effects and non-medical use, not efficacy, and studies on therapeutic applications are few and yield mixed results. The authors of both of the latest reviews assessed the certainty of evidence as very low. There is also no study that compared two pharmaceutical dried flowers differing only in declared content.

Is thirty percent the highest potency of dried flower available in Polish pharmacies?

Today, this is the upper limit of the pharmacy offer. Previously, this limit was lower, and there is no indication that it will remain static, which is why we keep the current list of items in one compilation of strains, rather than on this page.

Where does the range from 27 to 33 percent come from with a declaration of thirty percent?

From a tolerance of ten percent of the nominal value, which is allowed regarding the manufacturer's declaration. Thirty percent reduced by one-tenth gives twenty-seven, and increased by one-tenth gives thirty-three.

Do older studies on hemp describe the same raw material as today's?

No. A meta-analysis from the journal Addiction showed an increase in tetrahydrocannabinol concentration in subsequent years, so the material from earlier studies was, on average, weaker, and transferring those results to today's products underestimates exposure (PMID:33160291).

Does high declared potency last longer?

No. The onset and duration of an episode are determined by the method of administration, not the declared content. After vaporization, effects appear within minutes and last for several hours; after oral administration, everything shifts and extends.

Who decides on the choice of raw material potency for the patient?

The attending physician. Dried flower is a pharmaceutical raw material dispensed by prescription in category Rpw, and the choice of registered item requires knowledge of the diagnosis and other medications taken, which this website cannot replace.

Hemp flower is a pharmaceutical raw material dispensed by a doctor's prescription in the Rpw category. The material is for informational purposes only and does not replace medical advice or the decisions of the attending physician. Editorial text: redakcja ubucha.pl.